Evidence map›Paper›PMID 32648102›Full record

ArticleClinical rheumatology2020

The changing profile of ankylosing spondylitis in the biologic era.

John D Reveille, MinJae Lee, Lianne S Gensler, Michael M Ward, Mark C Hwang, Thomas J Learch, Amirali Tahanan, Laura Diekman, Mohammad H Rahbar, Mariko L Ishimori and 1 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Observational
  4. Observational
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

John D ReveilleDepartment of Internal Medicine, Division of Rheumatology, McGovern Medical School at The University of Texas Health Science Center Houston, 6431 Fannin St., Houston, TX, 77030, USA. John.D.Reveille@uth.tmc.edu.ORCID http://orcid.org/0000-0001-5950-0913
MinJae LeeDivision of Biostatistics, Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Lianne S GenslerDepartment of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA, USA.
Michael M WardNational Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
Mark C HwangDepartment of Internal Medicine, Division of Rheumatology, McGovern Medical School at The University of Texas Health Science Center Houston, 6431 Fannin St., Houston, TX, 77030, USA.
Thomas J LearchDepartment of Radiology, Cedars-Sinai Medical Center Los Angeles, Los Angeles, CA, USA.
Amirali TahananDepartment of Internal Medicine, Division of Clinical and Translational Sciences, McGovern Medical School at The University of Texas Health Science Center Houston, Houston, TX, USA.
Laura DiekmanDepartment of Internal Medicine, Division of Rheumatology, McGovern Medical School at The University of Texas Health Science Center Houston, 6431 Fannin St., Houston, TX, 77030, USA.
Mohammad H RahbarDepartment of Internal Medicine, Division of Clinical and Translational Sciences, McGovern Medical School at The University of Texas Health Science Center Houston, Houston, TX, USA.
Mariko L IshimoriDivision of Rheumatology, Cedars Sinai Medical Center Los Angeles, Los Angeles, CA, USA.
Michael H WeismanDivision of Rheumatology, Cedars Sinai Medical Center Los Angeles, Los Angeles, CA, USA.
The University of Texas Health Science Center at Houston · USCedars-Sinai Medical Center · USNational Institutes of Health · USThe University of Texas Health Science Center · USThe University of Texas Southwestern Medical Center · USUniversity of California, San Francisco · US

Funding

Center for Clinical and Translational Sciences (CCTS)UL1TR000371 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MCPHERSON, DAVID D · 2012 to 2016
$13.4M
The Genetic Basis of AS SusceptibilityP01AR052915 · NIAMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI REVEILLE, JOHN DUFFIN · 2006 to 2016
$10.9M
Institutional Career Development CoreKL2TR003168 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MILLER, CHARLES C · 2019 to 2023
$4.9M
Janssen Pharmaceuticals n.a.NCATS NIH HHS KL2 TR003168NIAMS NIH HHS P01-052915-06NIH Centers for Translational Science Award UL1TR000371Spondylitis Association of America N.A.
6 · The paper itself

Abstract

objectiveTo compare disease characteristics, comorbidities, and medication utilization of 1141 patients with ankylosing spondylitis (AS) with short (< 20 years) and long (≥ 20 years) disease duration enrolled in the Prospective Study of Outcomes in AS (PSOAS) study over three different periods of time and followed longitudinally.

methodsStudy visits were carried out every 6 months examining disease activity (Bath AS Disease Activity Index (BASDAI), C-reactive protein, erythrocyte sedimentation rate), functional impairment, depression, and medication utilization as well as radiographic severity. Groups were compared with regression models using generalized estimating equation, linear, and Poisson regressions after adjusting for sites and for patients withdrawing from the study at less than 2 years follow-up.

resultsOverall, AS patients with long disease duration were more likely to be married, white, receiving disability, and to be with higher functional impairment and radiographic severity, more uveitis, diabetes, hypertension, cardiovascular disease, and osteoporosis, and with less nonsteroidal anti-inflammatory drug (NSAID) and more opioid use than those with short disease duration. Current smoking decreased between 2002 and 2019 regardless of disease duration. Lower baseline NSAID and methotrexate/sulfasalazine use and higher TNF inhibitor usage were seen only in those with shorter disease duration, though NSAID use and functional impairment decreased over time in both groups. Disease activity, depression scores, and NSAID use decreased and anti-TNF use increased in those followed > 8 years.

conclusionsPatients with AS enrolling in this multicenter longitudinal cohort have different disease profiles and medication utilization over time, perhaps reflecting innovations in treatment and increasing disease awareness. Key Points • The use of NSAIDs, nonbiologic DMARDs, and prednisone has decreased over the past 16 years in patients with AS. • The use of anti-TNF agents has dramatically increased. • In treated patients, disease activity, depression scores, and functional impairment have decreased over time.

Indexed as

Biological ProductsSpondylitis, AnkylosingHumansProspective StudiesSeverity of Illness IndexTumor Necrosis Factor-alphaBiological ProductsTumor Necrosis Factor-alphaAnkylosing spondylitisClinical featuresComorbiditiesDisease progressionDrug therapy

Identifiers

PMID32648102
OpenAlexW3041621491

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.